148 related articles for article (PubMed ID: 36734848)
1. Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer.
Ravi H; Arias-Lorza AM; Costello JR; Han HS; Jeong DK; Klinz SG; Sachdev JC; Korn RL; Raghunand N
Radiol Imaging Cancer; 2023 Mar; 5(2):e220022. PubMed ID: 36734848
[TBL] [Abstract][Full Text] [Related]
2. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study.
Ramanathan RK; Korn RL; Raghunand N; Sachdev JC; Newbold RG; Jameson G; Fetterly GJ; Prey J; Klinz SG; Kim J; Cain J; Hendriks BS; Drummond DC; Bayever E; Fitzgerald JB
Clin Cancer Res; 2017 Jul; 23(14):3638-3648. PubMed ID: 28159813
[No Abstract] [Full Text] [Related]
3. Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents.
Siedek F; Muehe AM; Theruvath AJ; Avedian R; Pribnow A; Spunt SL; Liang T; Farrell C; Daldrup-Link HE
Eur Radiol; 2020 Mar; 30(3):1790-1803. PubMed ID: 31844962
[TBL] [Abstract][Full Text] [Related]
4. Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI.
Rashidi A; Baratto L; Theruvath AJ; Greene EB; Jayapal P; Hawk KE; Lu R; Seekins J; Spunt SL; Pribnow A; Daldrup-Link HE
Radiol Imaging Cancer; 2023 Mar; 5(2):e220080. PubMed ID: 36999999
[TBL] [Abstract][Full Text] [Related]
5. Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial Metastatic Disease and Metastasis Size.
Hamilton BE; Barajas R; Nesbit GM; Fu R; Ambady P; Taylor M; Neuwelt EA
AJR Am J Roentgenol; 2020 Dec; 215(6):1436-1442. PubMed ID: 33052739
[No Abstract] [Full Text] [Related]
6. Pretherapy Ferumoxytol-enhanced MRI for Metastatic Breast Cancer: A New Approach for Predicting Tumor Delivery of Macromolecular Therapeutics?
Daldrup-Link HE
Radiol Imaging Cancer; 2023 Mar; 5(2):e220183. PubMed ID: 36734849
[No Abstract] [Full Text] [Related]
7. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.
Sachdev JC; Munster P; Northfelt DW; Han HS; Ma C; Maxwell F; Wang T; Belanger B; Zhang B; Moore Y; Thiagalingam A; Anders C
Breast Cancer Res Treat; 2021 Feb; 185(3):759-771. PubMed ID: 33201358
[TBL] [Abstract][Full Text] [Related]
8. Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis.
Bernards N; Ventura M; Fricke IB; Hendriks BS; Fitzgerald J; Lee H; Zheng J
Mol Pharm; 2018 Sep; 15(9):4132-4138. PubMed ID: 30059232
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study.
Iv M; Samghabadi P; Holdsworth S; Gentles A; Rezaii P; Harsh G; Li G; Thomas R; Moseley M; Daldrup-Link HE; Vogel H; Wintermark M; Cheshier S; Yeom KW
Radiology; 2019 Jan; 290(1):198-206. PubMed ID: 30398435
[TBL] [Abstract][Full Text] [Related]
10. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
[TBL] [Abstract][Full Text] [Related]
11. Radiomics of Brain MRI: Utility in Prediction of Metastatic Tumor Type.
Kniep HC; Madesta F; Schneider T; Hanning U; Schönfeld MH; Schön G; Fiehler J; Gauer T; Werner R; Gellissen S
Radiology; 2019 Feb; 290(2):479-487. PubMed ID: 30526358
[TBL] [Abstract][Full Text] [Related]
12. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
[TBL] [Abstract][Full Text] [Related]
13. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
14. Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study.
Iv M; Ng NN; Nair S; Zhang Y; Lavezo J; Cheshier SH; Holdsworth SJ; Moseley ME; Rosenberg J; Grant GA; Yeom KW
Radiology; 2020 Nov; 297(2):438-446. PubMed ID: 32930651
[TBL] [Abstract][Full Text] [Related]
15. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Mohammad AS; Griffith JI; Adkins CE; Shah N; Sechrest E; Dolan EL; Terrell-Hall TB; Hendriks BS; Lee H; Lockman PR
Pharm Res; 2018 Jan; 35(2):31. PubMed ID: 29368289
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone.
Kosmin M; Padhani AR; Gogbashian A; Woolf D; Ah-See ML; Ostler P; Sutherland S; Miles D; Noble J; Koh DM; Marshall A; Dunn J; Makris A
Radiology; 2020 Dec; 297(3):622-629. PubMed ID: 33078998
[TBL] [Abstract][Full Text] [Related]
17. Ferumoxytol Does Not Impact Standardized Uptake Values on PET/MR Scans.
Muehe AM; Yerneni K; Theruvath AJ; Thakor AS; Pribnow A; Avedian R; Steffner R; Rosenberg J; Hawk KE; Daldrup-Link HE
Mol Imaging Biol; 2020 Jun; 22(3):722-729. PubMed ID: 31325083
[TBL] [Abstract][Full Text] [Related]
18. Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy.
Kwon BR; Shin SU; Kim SY; Choi Y; Cho N; Kim SM; Yi A; Yun B; Jang M; Ha SM; Lee SH; Chang JM; Moon WK
Radiology; 2022 Aug; 304(2):310-319. PubMed ID: 35536129
[TBL] [Abstract][Full Text] [Related]
19. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
Chen BB; Lu YS; Lin CH; Chen WW; Wu PF; Hsu CY; Yu CW; Wei SY; Cheng AL; Shih TT
BMC Cancer; 2016 Jul; 16():466. PubMed ID: 27412562
[TBL] [Abstract][Full Text] [Related]
20. Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial.
McDonald ES; Romanoff J; Rahbar H; Kitsch AE; Harvey SM; Whisenant JG; Yankeelov TE; Moy L; DeMartini WB; Dogan BE; Yang WT; Wang LC; Joe BN; Wilmes LJ; Hylton NM; Oh KY; Tudorica LA; Neal CH; Malyarenko DI; Comstock CE; Schnall MD; Chenevert TL; Partridge SC
Radiology; 2021 Jan; 298(1):60-70. PubMed ID: 33201788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
